Isentress Oral Suspension

— THERAPEUTIC CATEGORIES —
  • Viral infections

Isentress Oral Suspension Generic Name & Formulations

General Description

Raltegravir (as potassium) 100mg; per packet; pwd for oral susp; banana flavor.

Pharmacological Class

HIV-1 integrase strand transfer inhibitor (INSTI).

How Supplied

Chew tabs, film-coated tabs—60; Susp (pkts)—1, 60 (w. syringes, mixing cups)

Manufacturer

Isentress Oral Suspension Indications

Indications

HIV-1 infection, in combination with other antiretrovirals.

Isentress Oral Suspension Dosage and Administration

Adult

Use film-coated tabs.

Children

Pre-term neonates or <2kg: not recommended. Give first dose between 24–48hrs post birth if mother received raltegravir 2–24hrs before delivery. Mix susp packet contents with 10mL of water; administer using oral syringe within 30mins. Birth to 1 week (2–<3kg): 4mg (0.4mL) once daily; (3–<4kg): 5mg (0.5mL) once daily; (4–<5kg): 7mg (0.7mL) once daily. 1 to 4 weeks (2–<3kg): 8mg (0.8mL) twice daily; (3–<4kg): 10mg (1mL) twice daily; (4–<5kg): 15mg (1.5mL) twice daily. ≥4 weeks (3–<4kg): 25mg (2.5mL) twice daily; (4–<6kg): 30mg (3mL) twice daily; (6–<8kg): 40mg (4mL) twice daily; (8–<10kg): 60mg (6mL) twice daily; (10–<14kg): 80mg (8mL) twice daily; (14–<20kg): 100mg (10mL) twice daily; (20–<25kg): use chew tabs. Oral susp max dose: 100mg (10mL) twice daily. See full labeling.

Isentress Oral Suspension Contraindications

Not Applicable

Isentress Oral Suspension Boxed Warnings

Not Applicable

Isentress Oral Suspension Warnings/Precautions

Warnings/Precautions

Chew tabs or oral susp are not interchangeable with the film-coated tabs. Monitor liver aminotransferases, myopathy, and rhabdomyolysis. Discontinue if signs/symptoms of severe skin or hypersensitivity reactions develop. Hepatic impairment: Isentress HD not recommended. Pregnancy. Nursing mothers: not recommended.

Isentress Oral Suspension Pharmacokinetics

See Literature

Isentress Oral Suspension Interactions

Interactions

May be antagonized by UGT1A1 inducers (eg, rifampin; see Adult dose) and potentiated by UGT1A1 inhibitors. Concomitant aluminum and/or magnesium-containing antacids, other strong enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin): not recommended. Caution with concomitant drugs known to cause myopathy or rhabdomyolysis (eg, statins). Isentress HD: concomitant calcium carbonate antacid, rifampin, tipranavir/ritonavir, etravirine: not recommended.

Isentress Oral Suspension Adverse Reactions

Adverse Reactions

Insomnia, headache, dizziness, nausea, fatigue, creatinine kinase elevations, myopathy, rhabdomyolysis; severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), hypersensitivity, immune reconstitution syndrome.

Isentress Oral Suspension Clinical Trials

See Literature

Isentress Oral Suspension Note

Notes

Register pregnant patients exposed to raltegravir by calling (800) 258-4263.

Isentress Oral Suspension Patient Counseling

See Literature